| __timestamp | ADMA Biologics, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3742367 | 5758000 |
| Thursday, January 1, 2015 | 4311461 | 8423000 |
| Friday, January 1, 2016 | 6360761 | 11986000 |
| Sunday, January 1, 2017 | 29164321 | 15215000 |
| Monday, January 1, 2018 | 42194635 | 15356000 |
| Tuesday, January 1, 2019 | 39504238 | 16660000 |
| Wednesday, January 1, 2020 | 61291426 | 52459000 |
| Friday, January 1, 2021 | 79769341 | 75061000 |
| Saturday, January 1, 2022 | 118814535 | 87221000 |
| Sunday, January 1, 2023 | 169273000 | 83779000 |
Unlocking the unknown
In the ever-evolving landscape of biopharmaceuticals, understanding cost dynamics is crucial. ADMA Biologics, Inc. and Supernus Pharmaceuticals, Inc. offer a fascinating case study. From 2014 to 2023, ADMA Biologics saw a staggering 4,400% increase in its cost of revenue, peaking at $169 million in 2023. This reflects their aggressive expansion and investment in production capabilities. In contrast, Supernus Pharmaceuticals experienced a more modest 45% rise over the same period, reaching $83 million in 2023. This suggests a more stable growth strategy, focusing on efficiency and cost management. The data highlights the contrasting strategies of these two companies, offering insights into their operational priorities. As the biopharma sector continues to grow, these trends underscore the importance of strategic financial planning in maintaining competitive advantage.
Cost of Revenue Comparison: Sanofi vs Supernus Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Vertex Pharmaceuticals Incorporated and ADMA Biologics, Inc.
Cost of Revenue Comparison: United Therapeutics Corporation vs Supernus Pharmaceuticals, Inc.
Cost Insights: Breaking Down Bio-Techne Corporation and ADMA Biologics, Inc.'s Expenses
Catalent, Inc. vs ADMA Biologics, Inc.: Efficiency in Cost of Revenue Explored
Catalent, Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Exelixis, Inc. vs Supernus Pharmaceuticals, Inc.
Cost of Revenue Comparison: ADMA Biologics, Inc. vs Mesoblast Limited
Cost of Revenue: Key Insights for Veracyte, Inc. and Supernus Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for ACADIA Pharmaceuticals Inc. and Supernus Pharmaceuticals, Inc.
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc.'s Expenses
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Travere Therapeutics, Inc.'s Expenses